Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

STOPP/START Anti-aggregation and Anticoagulation Alerts in Atrial Fibrillation

Author(s): Francesco Salis*, Antonella Palimodde, Samuele Rundeddu and Antonella Mandas

Volume 21, Issue 3, 2023

Published on: 04 May, 2023

Page: [205 - 210] Pages: 6

DOI: 10.2174/1570161121666230418163016

Price: $65

Abstract

Background: Atrial Fibrillation (AF) is common in the elderly. A key component of AF management is Oral Anticoagulant Therapy (OAT), consisting of Vitamin K Antagonists (VKAs) or Direct Oral Anticoagulants (DOACs). The aim of the present study is to check, using STOPP (Screening Tool of Older Persons’ Prescriptions)/START (Screening Tool to Alert to Right Treatment) Criteria, if such drugs are potentially inappropriately prescribed/omitted in an elderly population with AF, and to determine their impact on mortality.

Methods: This study included patients (n = 427) with nonvalvular AF consecutively evaluated between 2013 and 2019 at the Geriatric Outpatient Service, University Hospital of Monserrato, Cagliari, Italy, and followed up for 36 months. The OAT group included 330 patients; the other 97 patients constituted the non-OAT group. The sample was assessed for STOPP/START criteria.

Results: We found no difference (p > 0.1) in comorbidity burden, frailty, and cardio-cerebro-vascular disease prevalence in the two groups, which also did not present a difference in 36-month mortality (p = 0.97). OAT was overall appropriately taken, and 62.4% of OAT-group presented the START criterion to take antiplatelets but also the STOPP criterion not to take them, because of the simultaneous anticoagulant intake. In the non-OAT group, 69.1% presented the START criterion to take anticoagulants, and 21.6% the START criterion to take antiplatelets.

Conclusion: Patients with AF are often prone to under or over-prescription, particularly of antithrombotic drugs. The STOPP/START criteria are a valid tool to assess and correct wrong therapeutic choices. In frail and comorbid subjects, survival is not correlated with the assumption of OAT.

« Previous Next »
Graphical Abstract

[1]
Rohrmann S. Epidemiology of frailty in older people. Adv Exp Med Biol 2020; 1216: 21-7.
[http://dx.doi.org/10.1007/978-3-030-33330-0_3] [PMID: 31894543]
[2]
Salis F, Loddo S, Zanda F, Peralta MM, Serchisu L, Mandas A. Comprehensive geriatric assessment: Application and correlations in a real-life cross-sectional study. Front Med 2022; 9: 984046.
[http://dx.doi.org/10.3389/fmed.2022.984046] [PMID: 36177326]
[3]
Laksmi PW, Harimurti K, Setiati S, Soejono CH, Aries W, Roosheroe AG. Management of immobilization and its complication for elderly. Acta Med Indones 2008; 40(4): 233-40.
[PMID: 19151453]
[4]
Salis F, Costaggiu D, Mandas A. Mini-mental state examination: Optimal cut-off levels for mild and severe cognitive impairment. Geriatrics 2023; 8(1): 12.
[http://dx.doi.org/10.3390/geriatrics8010012] [PMID: 36648917]
[5]
Robles N, Macias J. Hypertension in the elderly. Cardiovasc Hematol Agents Med Chem 2015; 12(3): 136-45.
[http://dx.doi.org/10.2174/1871525713666150310112350] [PMID: 25761101]
[6]
Salis F, Locci G, Mura B, Mandas A. Anemia in elderly patients—the impact of hemoglobin cut-off levels on geriatric domains. Diagnostics 2023; 13(2): 191.
[http://dx.doi.org/10.3390/diagnostics13020191] [PMID: 36673001]
[7]
Aronow WS. Atrial fibrillation. Heart Dis 2002; 4(2): 91-101.
[http://dx.doi.org/10.1097/00132580-200203000-00006] [PMID: 11975840]
[8]
Salis F, Palimodde A, Demelas G, Scionis MI, Mandas A. Frailty and comorbidity burden in Atrial Fibrillation. Front Public Health 2023; 11: 1134453.
[http://dx.doi.org/10.3389/fpubh.2023.1134453] [PMID: 36969648]
[9]
Kato ET, Goto S, Giugliano RP. Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation. Ageing Res Rev 2019; 49: 115-24.
[http://dx.doi.org/10.1016/j.arr.2018.10.006] [PMID: 30359765]
[10]
Jacobs LG. Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly. Cardiol Clin 2008; 26(2): 157-167, v.
[http://dx.doi.org/10.1016/j.ccl.2007.12.010] [PMID: 18406992]
[11]
Paikin JS, Hirsh J, Lauw MN, Eikelboom JW, Ginsberg JS, Chan NC. New oral anticoagulants for stroke prevention in atrial fibrillation: Impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. Thromb Haemost 2014; 111(5): 798-807.
[http://dx.doi.org/10.1160/TH13-11-0918] [PMID: 24553904]
[12]
Di Minno A, Frigerio B, Spadarella G, et al. Old and new oral anticoagulants: Food, herbal medicines and drug interactions. Blood Rev 2017; 31(4): 193-203.
[http://dx.doi.org/10.1016/j.blre.2017.02.001] [PMID: 28196633]
[13]
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138(5): 1093-100.
[http://dx.doi.org/10.1378/chest.10-0134] [PMID: 20299623]
[14]
Ogawa H, An Y, Ishigami K, et al. Long-term clinical outcomes after major bleeding in patients with atrial fibrillation: The Fushimi AF registry. Eur Heart J Qual Care Clin Outcomes 2021; 7(2): 163-71.
[http://dx.doi.org/10.1093/ehjqcco/qcaa082] [PMID: 33107912]
[15]
Undas A, Drabik L, Potpara T. Bleeding in anticoagulated patients with atrial fibrillation: Practical considerations. Kardiol Pol 2020; 78(2): 105-16.
[http://dx.doi.org/10.33963/KP.15205] [PMID: 32108755]
[16]
Bencivenga L, Komici K, Nocella P, et al. Atrial fibrillation in the elderly: A risk factor beyond stroke. Ageing Res Rev 2020; 61: 101092.
[http://dx.doi.org/10.1016/j.arr.2020.101092] [PMID: 32479927]
[17]
Bocchino PP, Angelini F, Toso E. Atrial fibrillation and coronary artery disease: A review on the optimal use of oral anticoagulants. Rev Cardiovasc Med 2021; 22(3): 635-48.
[http://dx.doi.org/10.31083/j.rcm2203074] [PMID: 34565066]
[18]
O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: Version 2. Age Ageing 2014; 44(2): 213-8.
[http://dx.doi.org/10.1093/ageing/afu145] [PMID: 25324330]
[19]
Loddo S, Salis F, Rundeddu S, Serchisu L, Peralta MM, Mandas A. Nutritional status and potentially inappropriate medications in elderly. J Clin Med 2022; 11(12): 3465.
[http://dx.doi.org/10.3390/jcm11123465] [PMID: 35743535]
[20]
Rodríguez-Blanco R, Álvarez-García M, Villalibre-Calderón C, Piña-Ferreras LD, Junquera-Alonso S, Alonso-Lorenzo JC. Evaluation of the update of the STOPP-START criteria in primary care. Semergen 2019; 45(3): 180-6.
[http://dx.doi.org/10.1016/j.semerg.2018.06.004] [PMID: 30545673]
[21]
Guo X, Li M, Du X, et al. Multimorbidity, polypharmacy and inappropriate prescribing in elderly patients with atrial fibrillation: A report from the China Atrial Fibrillation Registry Study. Front Cardiovasc Med 2022; 9: 988799.
[http://dx.doi.org/10.3389/fcvm.2022.988799] [PMID: 36148073]
[22]
Coupet M, Renvoize D, Rousseau C, Fresil M, Lozachmeur P, Somme D. Adequacy of cardiovascular prescriptions to good practice guides in the elderly according to the "STOPP and START" tools ». Gériatr Psychol Neuropsychiatr Vieil 2013; 11(3): 237-43. [Validity of cardiovascular prescriptions to the guidelines in the elderly according to the STOPP and START method].
[PMID: 24026128]
[23]
Dubois-Puechlong S, Mille F, Hindlet P, et al. Potentially inappropriate prescriptions of antithrombotic therapies in older outpatients: A French multicenter cross-sectional study. Eur Geriatr Med 2019; 10(3): 473-81.
[http://dx.doi.org/10.1007/s41999-019-00176-2] [PMID: 34652793]
[24]
Gentes É, Hertzog M, Vogel T, Lang PO. High frequency of potentially inappropriate cardiovascular drug prescriptions in the elderly population. Presse Med 2015; 44(2): e41-50.
[http://dx.doi.org/10.1016/j.lpm.2014.05.027] [PMID: 25535164]
[25]
Román-Villarán E, Alvarez-Romero C, Martínez-García A, et al. A personalized ontology-based decision support system for complex chronic patients: Retrospective observational study. JMIR Form Res 2022; 6(8): e27990.
[http://dx.doi.org/10.2196/27990] [PMID: 35916719]
[26]
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40(5): 373-83.
[http://dx.doi.org/10.1016/0021-9681(87)90171-8] [PMID: 3558716]
[27]
Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47(11): 1245-51.
[http://dx.doi.org/10.1016/0895-4356(94)90129-5] [PMID: 7722560]
[28]
Morley JE, Malmstrom TK, Miller DK. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. J Nutr Health Aging 2012; 16(7): 601-8.
[http://dx.doi.org/10.1007/s12603-012-0084-2] [PMID: 22836700]
[29]
Pamukcu B, Lip GYH, Lane DA. Simplifying stroke risk stratification in atrial fibrillation patients: implications of the CHA2DS2-VASc risk stratification scores. Age Ageing 2010; 39(5): 533-5.
[http://dx.doi.org/10.1093/ageing/afq059] [PMID: 20507847]
[30]
Su CH, Lo CH, Chen HH, et al. CHA2DS2-VASc score as an independent outcome predictor in patients hospitalized with acute ischemic stroke. PLoS One 2022; 17(7): e0270823.
[http://dx.doi.org/10.1371/journal.pone.0270823] [PMID: 35830440]
[31]
Chao TF, Chan YH, Chiang CE, et al. Continuation or discontinuation of oral anticoagulants after HAS-BLED scores increase in patients with atrial fibrillation. Clin Res Cardiol 2022; 111(1): 23-33.
[http://dx.doi.org/10.1007/s00392-021-01816-z] [PMID: 33704551]
[32]
Gladstone DJ, Wachter R, Schmalstieg-Bahr K, et al. Screening for atrial fibrillation in the older population. JAMA Cardiol 2021; 6(5): 558-67.
[http://dx.doi.org/10.1001/jamacardio.2021.0038] [PMID: 33625468]
[33]
Ruddox V, Sandven I, Munkhaugen J, Skattebu J, Edvardsen T, Otterstad JE. Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: A systematic review and meta-analysis. Eur J Prev Cardiol 2017; 24(14): 1555-66.
[http://dx.doi.org/10.1177/2047487317715769] [PMID: 28617620]
[34]
Goulart AC, Olmos RD, Santos IS, et al. The impact of atrial fibrillation and long-term oral anticoagulant use on all-cause and cardiovascular mortality: A 12-year evaluation of the prospective Brazilian Study of Stroke Mortality and Morbidity. Int J Stroke 2022; 17(1): 48-58.
[http://dx.doi.org/10.1177/1747493021995592] [PMID: 33527882]
[35]
Takahashi M, Okawa K, Morimoto T, et al. Impact of direct oral anticoagulant use on mortality in very old patients with non-valvular atrial fibrillation. Age Ageing 2022; 51(7): afac146.
[http://dx.doi.org/10.1093/ageing/afac146] [PMID: 35776672]
[36]
Hink U, Voigtländer T. Necessity of antiaggregation and anticoagulation and its prognostic impact: A cardiologist’s view. Visc Med 2020; 36(4): 264-73.
[http://dx.doi.org/10.1159/000509896] [PMID: 33005651]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy